Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Inovio’s Coronavirus Vaccine Makes INO Stock Worth a Bet

By Chris Lau, InvestorPlace Contributor

Speculators are betting that INO stock and its vaccine are coronavirus killers, but the biotechnology firm may be more than just that.

A Massive Market Opportunity Makes FuelCell Worth the Speculation

By Chris Lau, InvestorPlace Contributor

FuelCell is risky, but speculators still love it. FCEL stock will be a great buy if it posts consistent revenue and market share growth.

Get Creative and Buy the Dip in Pinterest as User Activity Surges

By Chris Lau, InvestorPlace Contributor

Pinterest continues to draw active users and boost relevant advertising on its site, making Pinterest stock a buy on the dip now.

Canopy Growth’s Future Is Still Very Bright

By Chris Lau, InvestorPlace Contributor

Canopy Growth reported strong sales numbers and updated investors on its U.S. expansion. CGC stock still looks bright.

New Financing Deals Will Improve Nio’s Long-Term Business

By Chris Lau, InvestorPlace Contributor

Nio stock looks better in the long term thanks to two new cash raises that add $200 million to the company's pocketbooks.

Load More